Purpose: We isolated a sub-line (CC531M) from the CC531S rat colon carcinoma cell line, which grows and metastasizes much more rapidly than CC531S. We found, using RNA expression profiling that one of the major changes in the CC531M cell line was a 5.8-fold reduction of the chemokine CXCL5. The purpose of this study was to determine the impact of CXCL5 expression on colorectal tumor growth and metastasis.
introduCtion Colorectal cancer is one of the three leading causes of cancer-related death among men and women in the western world 1;2 . Despite curative surgical resection of the primary tumor, 40 to 50 percent of the patients ultimately die of metastases 3 .
Tumor growth and metastasis result from a complex cascade of biological processes.
Therefore, knowing key factors in these processes is crucial to design new treatment modalities.
In a previous paper we reported the in vivo selection of an aggressive rat colorectal cell line (CC531M) from the well described CC531S cell line 4;5 . The present study was initiated to identify factors that contribute to rapid growth and metastatic capacity of CC531M. In this study we focus on the chemokine CXCL5.
CXCL5 is a member of the subfamily of lipopolysacharide (LPS)-inducible ELR + CXC chemokines 6 . It functions, mainly through interaction with the CXCR2 receptor, both as a chemoattractant and as an angiogenic factor [7] [8] [9] [10] . CXCL5 is expressed in the epithelial cells of the colon and over-expressed in colorectal cancer 11;12 . It has been reported that CXCL5 plays a role in development and metastasis of several cancer types [13] [14] [15] . CXCL5 contributes to the in vivo growth and angiogenic potential of non-small cell lung cancer (NSCLC). Homogenates of human NSCLC specimens were angiogenic in the rat corneal micropocket assay, and the development of vasculature can be blocked by antibodies that neutralize CXCL5 14 . The role of CXCL5, produced by colorectal tumors, in relation to cancer progression and prognosis is poorly understood.
In this study, we investigated expression of CXCL5 on tumor growth and metastasis in a colorectal tumor rat model. CC531 cells, expressing different levels of CXCL5, were inoculated in the livers of syngenic rats and both tumor formation and metastasis were determined. CXCL5 expression was determined in two different independent large panels of human colorectal tumors and correlated with clinical follow-up and T-cell infiltration data.
exPeriMentAl deSign

CC531S and CC531M cell lines and culture conditions
The rat colon carcinoma cell line CC531S was originally developed using dimethylhydrazin in Wag/Rij rats 5 . The aggressive CC531M was isolated from CC531S using an in vivo selection protocol 4;16 . Cells were cultured at 37°C and 5% CO 2 , in cell culture flasks (Corning, NY, USA) containing culture medium, composed of RPMI1640 (Gibco, Paisley, Scotland), supplemented with 10% heat-inactivated FCS, 100 μg/ml streptomycin, 100 IU/ml penicillin and 2 mM L-glutamine (all Gibco, Paisley, Scotland).
Development of CXCL5 knock-down and CXCL5 expressing CC531 clones
RNAi techniques were used to generate CC531S CXCL5 knock-down clones. A 19-nucleotide sequence (AACGGAGCTACGCTGTGTT), separated by a 9-nucleotide non-complementary spacer (TTCAAGAGA) from the reverse complement of the 19-nucleotide sequence, was cloned and sequenced after digestion with BglII and HindIII and inserted into the pSUPER backbone (OligoEngine, Seattle, USA), using standard procedures. To obtain stably transfected CC531S CXCL5-knock-down and control clones, the pSUPER-CXCL5 siRNA or empty vectors were co-transfected with the pcDNA3 vector, using Lipofectamine2000 (Invitrogen, California, USA). Three CXCL5-knock-down CC531S clones (S1 CXCL5-, S2 CXCL5and S3 CXCL5-) and three control clones (S4 Control , S5 Control and S6 Control ) were selected.
To restore CXCL5 expression in CC531M clones, CXCL5 was amplified by routine PCR using cDNA derived from CC531S. Forward and reversed primers were designed, using the first or last complementary 20 base pairs in addition of a HindIII or EcoRI sequence respectively. In front of the initial ATG code a KOZAK sequence was placed.
PCR products were directly cloned with the pGEM-T-Easy cloning kit (Promega, Wisconsin, USA) and sequenced. Expression plasmids for CXCL5 were obtained, through unidirectional cloning of the sequence into the mammalian expression vector pcDNA3 (Invitrogen, California, USA). To obtain stably transfected CC531M CXCL5expressing and control clones, CC531M cells were transfected with pcDNA3-CXCL5 or control empty vector. Two CC531M clones expressing CXCL5 (M1 CXCL5+ and M2 CXCL5+ ) and two control clones (M3 Control and M4 Control ) were selected. Selection was based upon expression of CXCL5 as indicated by immunostaining. Stably transfected clones were grown under selective pressure, in culture medium supplemented with 200μg/ ml G418 (Sigma, St. Louis, MO, USA).
Immunocytochemistry
Cells were cultured on 12-mm glass coverslips and stained as previously described 17 , using the primary antibody rabbit anti-murine LIX 18 (Peprotech EC Ltd, London, UK) and Cy3-conjugated goat anti rabbit secondary antibody (Jackson, Suffolk, UK) in TBP (1h RT). Finally, cells were stained with 2 μg/ml Hoechst 33258 (Invitrogen, California, USA). Cells were analyzed using a Nikon Eclipse E600 fluorescence microscope with a 40x plan fluor Nikon objective (Nikon, Tokyo, Japan). The percentage CXCL5 positive tumor cells and the CXCL5 pixel intensity per cell were determined. For every clone or cell line at least 5 randomly chosen fields were analysed to determine the percentage of CXCL5 positive cells. CXCL5: a key factor in colorectal cancer 61
Cell proliferation
DNA content was used to determine the proliferation rate of CC531 cells and clones by a method previously described 19 . In short: 25000 cells were seeded into a 24 well plate. Medium was replaced daily. From 24h up to 144h after the start of seeding cells, each day plates were removed, rinsed with PBS, and stored at -80°C until assayed. On the day of assay, cells were thawed, 200 μl of distilled water was added (1h at 37°C). The plates were frozen at -80°C and thawed. From each well 50μl was taken and placed into a 96 well plate. DNA content was determined after addition of 50μl of 20μg/ml Hoechst 33258 fluorochrome (Invitrogen, California, USA) and measured on a fluostar optima platereader (BMG Labtech GmbH, Offenburg, Germany).
Rat experiments
All animal experiments were approved by the animal experiment committee of Leiden University. Animals were kept in our own animal facilities. Male Wag/Rij rats (Charles River, Zeist, The Netherlands) were anesthetized with halothane, underwent laparotomy, and were double blind randomized for induction of a liver tumor. A suspension of 5*10 4 viable CC531 tumor cells in 50μl was injected sub-capsulary at four sites into the liver. Per clone, four rats were inoculated. Rats were sacrificed by abdominal bleeding under halothane anesthesia, liver and tumor were removed and weight was determined. To determine the number of lung metastasis, lungs were removed and filled with an ink solution, as previously described 20;21 .
RT-PCR of CXCL5 in a patient cohort
Tumours from a cohort of 70 patients that were curatively treated by surgery for colorectal cancer, between 1990 and 2001, were used to associate level of CXCL5 RNA expression with prognosis. Fifty percent of the patients were female. The mean age at the time of surgery was 67.2 years. Tumors were staged according to the American Joint Committee on Cancer (AJCC) criteria 22 on an ABI Prism 7900ht (Applied Biosystems) using the SybrGreen RT-PCR core-kit (Eurogentec, Seraing, Belgium). Cycle conditions were 10 minutes at 94°C followed by 40 cycles of 10 s at 94°C and 1 minute at 60°C. Cycle threshold extraction was performed using the SDS software (version 2.2.2, Applied Biosystems). For all PCRs, a standard curve was generated using a five-step, five-fold dilution of pooled cDNA from the HCT81 colorectal cancer cell line. Relative concentrations of mRNA for each gene were calculated from the standard curve. After RT-PCR, dissociation curves were made to check the quality of the reaction. Reactions with more than one peak in the dissociation curve were discarded. For normalization, the expression values for each gene were divided by the normalization factor of the gene (the average of the three house keeping genes).
Immunohistochemistry of CXCL5 in a patient cohort
In a second independent cohort of 58 patients, curatively operated for colorectal cancer was used to associate protein level of CXCL5 to prognosis. The cohort comprised immunohistochemistry was performed on 4-μm paraffin tissue sections, including blockage of endogenous peroxidise, EDTA antigen retrieval (not for CXCL5 detection) and di-aminobenzidine development. To be able to distinguish intra-epithelial from stromal infiltration, an additional staining for laminin was performed on CD4 and CD8 stained sections, including trypsin antigen retrieval and development using NBT/BCIP solution, as previously described 23 . The following primary antibodies were used: the mAb anti-CXCL5 (clone MAB254, R&Dsystems, Minneapolis, USA), the mAb anti-CD4 (clone 1F6, Novocastra, UK), the mAb anti-CD8 (clone 4B11, Novocastra, UK) and rabbit anti-human laminin polyclonal Ab (Sigma-Aldrich, USA). Secondary reagents used were anti Mouse HRP EnVision+ (K400111, Dako, USA), biotinylated swine anti-rabbit IgG antibodies (DAKO Cytomation, Denmark), and biotinylatedperoxidase streptavidin complex (SABC; DAKO Cytomation, Denmark). CXCL5 expression was scored by microscopically assessing the percentage CXCL5 positive tumor of the whole section. Infiltration in the tumor tissue was scored in three compartments of the tumor tissue, i.e. intra-epithelially, intra-stromally and in the advancing tumor margin. Method of scoring has previously been described 23 .
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Statistical analysis
All analyses were performed with SPSS statistical software (version 12.0 for Windows, SPSS Inc, Chicago, IL). Mann-Whitney U test was used to compare variables. Kaplan-Meier analyses were performed to analyze patient survival. The entry date for the survival analyses was the time of surgery of the primary tumor. Events for time to disease free survival were defined as follows: from time of surgery to time of disease relapse or death. Events for time to cancer specific survival were defined as follows: from time of surgery to time of disease relapse or death by disease. Cox' regression analyses were used to calculate Hazard Ratios (HR) with 95% confidence intervals (CI). Variables with a p-value of ≤0.10 in the univariate analyses were subjected to a multivariate analysis. Pearson's product-moment correlation was used to analyze correlations between level of CXCL5 expression and T-cell infiltration.
reSultS
Expression of CXCL5 is lost in CC531M compared to CC531S cells
We showed previously that subcapsular inoculation of the colorectal cell line, CC531M
in the liver of rats resulted in rapid tumor growth and induction of larger number of metastases as compared to inoculation of the parental CC531S 4 . Affymetrix micro array analysis was performed in triplicate to determine differences in gene expression between the parental cell line CC531S and CC531M. The major change was a 5.8-fold (SD=0.7) reduction of CXCL5 RNA content in CC531M cells as compared to expression in CC531S. To confirm RNA expression data, cells were stained for the presence of CXCL5 protein using immuno-fluorescence techniques. In CC531S cells a strong cytoplasmic staining was found, while CC531M cells hardly showed any staining ( figure 1A ). The percentage of CXCL5 positive cells was significantly (p<0.0001) higher in CC531S cells compared to CC531M cells ( figure 1B) . In vitro, CC531S and CC531M showed the same proliferation rate ( figure 1C ).
Knock-down of CXCL5 expression results in aggressive tumor growth in vivo
To study the contribution of CXCL5 to tumor outgrowth and metastatic potency of CC531S cells, RNAi technology was used to knock-down CXCL5 in this cell line. Three CXCL5 siRNA transfected CC531S clones (S1 CXCL5-, S2 CXCL5and S3 CXCL5-) and three control clones (S4 Control , S5 Control and S6 Control ) transfected with the empty vector, were selected. Immuno-fluorescence staining for CXCL5 expression showed a significant (p<0.0001) CXCL5 down-regulation in S1 CXCL5-, S2 CXCL5and S3 CXCL5compared to S4 Control , S5 Control and S6 Control ( figure 2A) . In vitro, no significant difference in mean proliferation rate was found between CC531S CXCL5 knock-down clones and control clones ( figure 2B ). To study the effect of loss of CXCL5 in CC531S on tumor formation, each individual clone was subcapsularly injected in the liver of four rats. At sacrifice, rats injected with clones S1 CXCL5or S2 CXCL5showed large tumors over-growing the whole liver and, in addition, also large tumor masses in the peritoneal cavity and lungs were found. Due to the massive tumor outgrowth it was impossible to determine weight and surface of the individual tumors of rats inoculated with clones S1 CXCL5or S2 CXCL5-. Therefore, the weight of both tumor and liver of all rats was determined.
The third clone, CC531S clone S3 CXCL5-, showed somewhat less aggressive outgrowth: the 3 control clones, S5 Control , showed 4 small tumors at the place of inoculation, the others (S4 Control , S6 Control ) did not show any tumor formation in the liver. The average weight of tumor and liver of the three CXCL5 knock-down clones was significant (p=0.001) higher than the control clones ( figure 2C ). Furthermore, injection of CXCL5 knock-down clones resulted in significant more lung metastases compared to the control CC531S clones (p=0.007) ( figure 2D ). Images of in vivo tumor growth are displayed in figure 3 . Together, these results show that while knock-down of CXCL5
in vitro did not result in difference in proliferation rate; in vivo CXCL5 knock-down in CC531S resulted in aggressive tumor growth accompanied with increased formation of metastases.
Restoration of CXCL5 expression results in less aggressive tumor growth in vivo
Stable transfection of CXCL5 into CC531M cells was used to study whether restored expression of CXCL5 would inhibit tumor growth and metastasizing capacity of CC531M in vivo. Two CXCL5 transfected clones (M1 CXCL5+ and M2 CXCL5+ ) and two In a second independent cohort of colorectal cancer patients, the protein level of 
CxCl5
High 50 (86%) ------0.009 1 0.01
Low ---8 (14%) 3.6 (1.3 -9.9) NOTE: Table 2 NOTE: a trend for positive correlation between expression of CXCL5 and intratumoral T-cell infiltration was found. T-cell infiltration was scored in different compartments of the tumor: intraepithelial, stromal, and at the advancing margin. Infiltration in each of these different compartments was associated to protein expression of CXCL5 using Pearson's product-moment correlation.
diSCuSSion
Many chemokines play a pivotal role in colorectal cancer 24 . We decided to study CXCL5 because our initial rat experiments indicated that the absence of this chemokine was associated with an aggressive tumor phenotype. CXCL5, an important homeostatic factor in the colon, is mainly produced in epithelial cells and is in general more highly expressed in cancer tissue compared to normal tissue 11;12 . This pattern, higher expression in tumor tissue than in normal tissue was also found in our experi- for tumor formation in vivo was confirmed by comparing the growth of transfected CC531 clones that expressed either high or low levels of CXCL5. Importantly, our findings in the rat proved to be relevant for colorectal cancer patients as in two different tumor tissue cohorts of these cancer patients, low expression of CXCL5 was associated with shorter survival.
Well established is the chemo-attraction of neutrophils into inflamed regions after CXCL5-CXCR2 interaction 9;26 . Antagonists to the CXCR2 receptor prevent neutrophil attraction and reduce the inflammatory response 27;28 . CXCR2 is also involved in chemokine-induced migration of NK and T-cells 28;29 . CXCL5 produced by tumor cells may attract CXCR2 expressing leukocytes as T-cells, NK cells and neutrophils, triggering an anti-tumor immune response. A trend for positive correlation between level of CXCL5 and intratumoral cytotoxic T-cell infiltration was found. This trend was not found for infiltration in the advancing border of the tumor, suggesting that CXCL5 indeed especially contributes to intratumoral infiltration of cytotoxic T-cells.
High tumor infiltration of these inflammatory immune cells is positively associated with good prognosis in colorectal cancer [30] [31] [32] . This concept that over-expression of specific chemokines causes tumor infiltration by distinct leukocyte subsets, resulting in tumor regression and tumor specific immunity, has also been described for other chemokines [33] [34] [35] [36] [37] [38] [39] [40] [41] . Thus, CXCL5 may contribute to an anti-tumor response.
Another mechanism by which CXCL5 may be involved in colorectal tumor growth is based on the fact that the CXCR2 receptor has been found on colorectal tumor cells 42-44 . Expression of CXCR2 has also been found in CC531 cells (unpublished data).
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This may indicate that CXCL5 functions as an autocrine growth inhibitory factor. This is in contrast with other reports that described a positive effect of CXCR2 ligands on tumor growth 43;44 . In our results the presence or absence of CXCL5 expression had no influence in vitro on proliferation rate of any of our cell lines. Moreover, we found in vivo that low expression of CXCL5 promotes tumor growth. These data indicate that the effect of CXCL5 is not very likely to depend on an autocrine signaling pathway.
CXCL5 may play opposing roles in tumor formation in general. On the one hand CXCL5 may induce an anti-tumor response by chemo-attraction of immune cells; on the other hand it may promote angiogenesis that supports tumor growth.
Our results indicate that in colorectal cancer formation, the anti-tumor response is dominant. In support of our results for head and neck squamous cell carcinoma HNSCC higher expression of CXCL5 was also found in mortal tumors associated with a better prognosis compared to immortal tumors having a poorer prognosis 45 . In other cancers a tumor promoting role for CXCL5 has been reported 13-15;46 . Arenberg et al. found a strong correlation between levels of CXCL5 and the level of vascularitzation in human NSCLC. In addition they showed, using a SCID mouse model that expression of CXCL5 in developing human NSCLC correlated with tumor growth 14 .
The data presented by Arenberg and others may seem in contrast with our findings.
However, in addition to the different tumor type studied, our findings were derived from a syngeneic rat model for colorectal cancer, with a competent immune system, while their results were obtained in immune deficient mouse models. Therefore, in the study by Arenberg et al. the potential effect of a CXCL5-dependent immune response on tumor development would not have been manifested.
In conclusion, our results show that CXCL5 is an important factor in growth and development of colorectal cancer. Our data suggest that expression of CXCL5 by tumor cells enhances the recruitment of tumor infiltrating lymphocytes thereby bringing about better prognosis in colorectal cancer patients. Therefore CXCL5 should be further studied for its potential role as a therapeutic target and prognostic biomarker in colorectal cancer.
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